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Abstract
Background: Successfully managing diabetes is a complex process that includes addressing issues
of drug efficacy, safety and treatment satisfaction. Additionally, the combined impact of patient/
disease characteristics and treatment outcomes on treatment satisfaction is not well understood.
The purpose of this study was to examine the impact of age, weight, gender, co-morbid conditions,
diabetes history, treatment burden, efficacy (HbA1c) and side effects (weight gain, hypoglycemic
events) on patients' appraisal of treatment satisfaction using linear regression models.
Methods: Data from a multi-center, randomized clinical trial comparing the efficacy/safety of
biphasic insulin aspart 70/30 (BIAsp 70/30) vs. glargine (Glar) among insulin naïve type 2 patients
were analyzed. Subjects were between ages 18–75, with baseline HbA1c > 8% and BMI ≤ 40 kg/m2
(N = 233). Treatment satisfaction was assessed by the Insulin Treatment Satisfaction Questionnaire
(ITSQ).
Results: When factors were examined independently, multiple significant relationships (age, co-
morbidity, hypoglycemic events, and weight gain) with overall and/or domains of treatment
satisfaction were found. However, when all significant relationships were examined together, only
neuropathy, treatment efficacy, and number of hypoglycemic events maintained their previous
significance.
Conclusion: By examining predictors independently, significant relationships were identified.
However, not all findings remained significant when examined in combination with each other.
Thus, to more accurately characterize the impact of factors on treatment satisfaction, a more
comprehensive approach may be necessary. By improving patient treatment satisfaction, the
efficacy of treatments, as well as critical treatment outcomes such as compliance and cost of care
should be improved.
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Successfully managing diabetes is a complex process and
must address not only issues of drug efficacy and safety
but also treatment satisfaction. Weaver and colleagues [1]
defined treatment satisfaction as the patient's view of the
treatment process and its associated outcomes based on
predefined criteria. Treatment satisfaction is a key patient-
reported outcome as it has been found to impact patient
compliance [2,3], cost of care [4,5], and self-management
behaviors [6]. Treatment satisfaction has also been shown
to significantly differ between the array of drug treatment
options available to clinicians for a given patient [7,8]. It
may at times be more sensitive to change than quality of
life, and has the ability to distinguish treatments with
equivalent efficacy [9]. Persons with diabetes who per-
ceive injecting insulin as burdensome may experience
more negative health outcomes [10], whereas patients
who are satisfied with their treatments are more likely to
maintain positive physical and psychological health [11].
Understanding the elements of treatment satisfaction for
diabetes is especially important, given the ever increasing
range of treatment options for diabetes patients as treat-
ment satisfaction expectations have been shown to be
dynamic and changing with the introduction of new ther-
apies [12].
Overall treatment satisfaction in diabetes consists of the
patient's appraisal of 3 main treatment-related parame-
ters: side effects, burden/inconvenience, and efficacy
[13,14]. In diabetes, appraisal of side effects may predom-
inantly include factors such as weight gain or the occur-
rence of hypoglycemic events. Appraisal of inconvenience
or burden may take into consideration number of injec-
tions or type of delivery device. The gold standard for
assessing efficacy is generally considered to be improve-
ment in HbA1c level, although it is unclear if diabetes
patients are aware of their exact values when not enrolled
in a clinical trial. Additionally, patient and disease charac-
teristics such as age, gender, time with diabetes, and prev-
alence and incidence of co-morbid conditions may act as
mediators that influence these appraisals.
Static factors such as patient and disease characteristics are
generally constant or fixed at any given point in time.
Characteristics such as age, gender, level of education, eth-
nicity and duration of diabetes have been shown to
account for some of the differences in patients' treatment
satisfaction with their diabetes care when provided by
endocrinologists compared to generalists [15]. However,
data on the relationship of these factors to treatment sat-
isfaction is often times conflicting, and many significant
relationships do not endure when examined in combina-
tion with other important factors. For example, studies
have found that greater satisfaction is associated with
decreasing age, while others have indicated that younger
patients are less satisfied with their treatment [16-18]. The
occurrence of diabetes-related complications has been
found to be associated with lower treatment satisfaction
with diabetes medication, however, this association was
no longer found when age, therapy and HbA1c level were
also taken into consideration [17]. Insulin-treated
patients have been found to have significantly greater
treatment satisfaction than non-insulin treated patients
with diabetes, though this significant difference was also
lost after adjustments were made for age, gender, body
mass index and duration of diabetes [19].
When examining treatment outcome factors which influ-
ence the appraisal of treatment satisfaction in diabetes,
the most universal finding is that treatment satisfaction
has generally been shown to be greater for those treat-
ments that are most efficacious [13,17,20]. Additionally,
clinical wisdom assumes that patients prefer treatments
with few injections and few side effects such as weight
gain or hypoglycemic events, although the data support-
ing these assumptions is not extensive and is contradic-
tory [1]. For treatments with equal efficacy and no
significant differences in weight gain or occurrence of
hypoglycemic events, significant differences in treatment
satisfaction have not been found [21]. Despite significant
improvement in treatment satisfaction after 7 months of
efficacious treatment (improved HbA1c) with decreased
hypoglycemic events and increased weight, a significant
relationship between weight gain, HbA1c and treatment
satisfaction has not been found [22]. Interestingly, fewer
number of daily injections has been shown both to
improve treatment satisfaction and to have no impact on
treatment satisfaction [23,24]. Further, continuous subcu-
taneous insulin infusion has been shown to be both supe-
rior to multiple daily injections, as well as to have no
impact in determining patient treatment satisfaction
[25,26].
Thus, it remains unclear what part of our beliefs about the
relationships between patient/disease characteristics, clin-
ical wisdom and treatment satisfaction in diabetes is myth
versus reality. The purpose of this study was to examine,
in the context of a randomized clinical trial (RCT), the
correlative relationship between treatment satisfaction,
patient/disease characteristics, and key treatment out-
comes that impact the appraisal of treatment satisfaction.
By understanding the myths vs. the realities of these rela-
tionships, clinicians will be in a better position to identify
patients at risk for decreased treatment satisfaction and
tailor treatment plans to maximize treatment satisfaction.
By improving patient treatment satisfaction, the efficacy
of diabetes treatments as well as other critical treatment
outcomes such as compliance and cost of care is likely to
be improved.Page 2 of 10
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Procedures
Baseline and end of study (28 weeks) data from the INITI-
ATE trial, a multi-center (25 U.S. sites) open-label RCT
comparing the efficacy and safety of twice-daily (BID)
biphasic insulin aspart 70/30 (BIAsp 70/30) vs. once-
daily, bedtime (QD) glargine (Glar) among insulin naïve
type 2 patients failing oral medication were analyzed. Eli-
gible subjects had type 2 diabetes inadequately treated,
controlled on oral antidiabetic agents (OADS), were insu-
lin naïve, and male or female between the ages of 18–75
with baseline HbA1c > 8% and BMI ≤ 40 kg/m2. Patients
with a history of recurrent, severe hypoglycemia, hepatic
or renal insufficiency, cardiac disease, acute or chronic
metabolic acidosis, active proliferative retinopathy or
intolerance to metformin were excluded from the study.
The first phase of the study was a 4 week run-in period
with metformin with patients with a fasting blood glucose
level of ≤ 140 mg/dL, or any single value ≤ 170 mg/dL
considered a run-in failure. Patients who successfully
completed the run-in period were then randomized to
receive equal doses of BIAsp 70/30 within 15 minutes
before breakfast and dinner in addition to their current
metformin or Glar at bedtime in addition to their current
metformin treatment. Subjects were told to perform daily
blood glucose self-monitoring before breakfast and din-
ner. Insulin doses were titrated weekly for the first 12
weeks, then every 2 weeks thereafter according to a pre-
defined titration algorithm based on blood glucose levels
for the 3 days preceding a visit. Post-randomization, sub-
jects were seen in the office weekly for the first month, and
then again at weeks 8, 12, 16, 20, 24 and 28. Phone visits
were conducted for weeks in which there was no office
visit. Patients in the INITIATE trial signed informed con-
sent forms and the study complied with FDA Good Clini-
cal Practices. The study protocol had IRB approval.
Measures
The following data were derived from and/or generated
during the trial and were used for the present analyses:
• Patient characteristics and diabetes history including age
(as a continuous variable), sex, ethnic group, time with
diabetes (at baseline as a continuous variable), body mass
index (BMI) and co-morbid conditions (classified as dia-
betes-related condition and as total number of condi-
tions). These data were collected at the baseline visit.
• The Insulin Treatment Satisfaction Questionnaire
(ITSQ) [11]: a validated measure consisting of 22 items
that comprehensively assess treatment satisfaction for per-
sons with diabetes on insulin. The measure was developed
as a patient-reported outcome based on interviews with
patients and clinical experts regarding treatment satisfac-
tion as well as information in the literature. Satisfactory
factor structure and internal consistency as well as ade-
quate test-retest reliability, construct and discriminant
validity for the ITSQ have been demonstrated [11]. In
addition to an Overall score, the items make up five
domains of satisfaction: Inconvenience of Regimen (IR-5
items), Lifestyle Flexibility (LF-3 items), Glycemic Control
(GC-3 items), Hypoglycemic Control (HC-5 items) and
Insulin Delivery Device (DD-6 items). All items are scored
on a seven-point Likert-like response scale ranging from
"not at all" to "extremely" (as worded appropriately for
item). Items in the Glycemic and Hypoglycemic Control
subscales are worded so that the respondent is asked
about the relevant symptoms of their control such that a
clinical understanding of either is not required. The ITSQ
is scored by transforming all items to a scale of 0–100 with
the higher score indicating better treatment satisfaction.
For each subscale, the sum score is divided by number of
items. Missing values are imputed based on the mean of
the non-missing items. The ITSQ was administered after
28 weeks of treatment.
• Diabetic treatment effect status assessed after 28 weeks
of treatment:
- HbA1c level
- Hypoglycemic episodes classified as total number, by
timing of event (classified as day or night), and by type of
event (classified as symptomatic or not)
- BMI classified as BMI group (< 25 as normal, between 25
and 29.9 as overweight, and ≥ 30 as obese) and by abso-
lute value change (classified as improved or worsened)
Statistical strategy
According to an a priori statistical analysis plan, for each
statistical test performed, the relationship between the
factors of interest, overall satisfaction and satisfaction
within each domain of the ITSQ was examined by linear
regression with listwise entry (all variables entered as a
block to test interaction with treatment satisfaction as the
dependent variable). Statistical significance was consid-
ered to be achieved with a minimum P value of 0.05.
Examining the relationship between patient and disease 
characteristics and treatment satisfaction
First, in order to confirm successfully randomized
cohorts, differences between treatment groups for base-
line patient and disease characteristics were examined by
ANOVA or chi square as appropriate for each characteris-
tic.
Next, a listwise linear regression analysis was performed
to examine baseline predictors of treatment satisfaction
assessed at week 28. The model included all demographicPage 3 of 10
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gender, ethnicity, duration of diabetes diagnosis, BMI,
and number/type of diabetes-related co-morbid condi-
tions). Independent linear regression models were
assessed for each of the ITSQ subscales and the Overall
score.
The relationship of total number of co-morbid conditions
and treatment satisfaction (each subscale and Overall)
was examined by Pearson correlations. Additionally, the
relationship between types of diabetes-related co-morbid
conditions and treatment satisfaction was examined by
independent linear regression (listwise) analyses of the
diabetes-related co-morbid conditions found in this sam-
ple and treatment satisfaction.
Examining the relationships between treatment outcomes and 
treatment satisfaction
The relationship between the number of minor hypoglyc-
emic events and treatment satisfaction was assessed by
Pearson correlation (2-tailed). Type of event (sympto-
matic or not) and time of event (day or night), cumulative
over the treatment period, and treatment satisfaction were
examined by linear regression analyses independently for
each subscale and Overall ITSQ score.
The relationship between BMI change during treatment
and treatment satisfaction (Overall and all subscales) was
first examined by performing an ANOVA, controlling for
baseline weight, using change in BMI group from baseline
to week 28. An independent ANOVA, controlling for base-
line weight, examined the relationship between absolute
changes in BMI, comparing those who had improved BMI
to those whose BMI had worsened over the 28 weeks.
The relationship between HbA1c levels at week 28 and
treatment satisfaction was examined by Pearson correla-
tion coefficients.
The relationship between treatment group and treatment
satisfaction was examined by ANOVAs for the total ITSQ
score and each of its domains.
Examining the combined impact of significant factors
Lastly, as outlined in the statistical analysis plan, to under-
stand the larger picture of the impact of demographic and
treatment effect variables on treatment satisfaction, a
regression analysis was performed on all of the above fac-
tors that were found to have a significant relationship to
treatment satisfaction at week 28. Variance and goodness-
of-fit was examined by the R2.
Results
Sample description
A total of 233 patients with Type 2 diabetes, a slight
majority of which were male (52.9%) and Caucasian
(51.7%) with an average age of 52.15 (± 10.34) years,
were randomized into the INITIATE study. Two hundred
and nine (209) of these subjects had treatment effect data
and 197 of these completed the ITSQ and were included
in these analyses. The average duration of diabetes diag-
nosis was 8.29 years (± 5.24), and mean baseline HbA1c
was 9.71% (± 1.47%).
Statistical findings
INITIATE trial clinical results
The INITIATE trial demonstrated that patients receiving
BIAsp 70/30 were significantly more likely to have
achieved HbA1c targets vs. Glar (66% vs. 40% of patients
to HbA1c < 7%, p < 0.01, and 42% vs. 28% of patients to
HbA1c ≤ 6.5%, p < 0.05, respectively), and significantly
improving total HbA1c reduction (-0.43%; p < 0.01
between arms). Post-prandial glucose excursions at lunch
and supper were also significantly more tightly controlled
(p < 0.05), though an increase in minor hypoglycemia
and weight gain occurred (both p < 0.05) [27].
Examining the relationship between patient and disease 
characteristics and treatment satisfaction
There were no significant differences found between treat-
ment groups for any of the baseline patient or disease
characteristics, indicating that randomization of subjects
to treatment groups used in the present analyses was suc-
cessful.
As shown in Table 1, presence of diabetes-related co-mor-
bid conditions at baseline was significantly predictive of
overall treatment satisfaction as well as for Lifestyle Flexi-
bility and in the Hypoglycemic and Glycemic Control
subscales. Age was also predictive of treatment satisfaction
related to Lifestyle Flexibility.
The number of total co-morbid conditions in the sample
ranged from 0 to 7 with a mean of 1.70 (± 1.50) and a
median of 1.00. The diabetes-related co-morbid condi-
tions identified in this sample were retinopathy, nephrop-
athy, neuropathy, and macro-angiopathy. There were no
significant relationships between total number of co-mor-
bid conditions and treatment satisfaction. However, neu-
ropathy was a significant predictor of treatment
satisfaction (overall and in all subscales), indicating that
pain is broadly associated with satisfaction outcomes.
One other noted predictor was retinopathy, which was
significant for the Device Satisfaction subscale. The rela-
tionship between types of diabetes-related co-morbid
condition and treatment satisfaction is shown in Table 2.Page 4 of 10
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treatment satisfaction
A total of 1,073 hypoglycemic events, of which 1,072 were
minor events, were reported over the 28 weeks of treat-
ment. Hence, the analysis is based on minor hypoglyc-
emic events only. The number of minor hypoglycemic
events per patient was found to be significantly associated
only with the Hypoglycemic Control subscale (r = -0.263,
p < 0.001). However, as shown in Table 3, the time of a
hypoglycemic event was found to be highly predictive of
overall treatment satisfaction and for each subscale, with
daytime events resulting in decreased treatment satisfac-
tion. There were no significant impacts for the type of
hypoglycemic event.
The majority of patients (81%) did not change BMI group
(normal, overweight or obese) during the treatment
period, and no significant relationships between BMI
group change and treatment satisfaction were found. The
absolute BMI change ranged from -2.57 (decrease) to
+6.83 (mean 1.61 ± 1.62) with the majority of the popu-
lation (85.5%) increasing in BMI levels. For those 14.5 %
of patients who had a decrease in BMI, there was a system-
atic improvement in treatment satisfaction across all
scores, although only the difference for the Lifestyle Flexi-
bility subscale was significant (p < 0.05). The lack of sta-
tistical significance may be due to the small number of
patients who did change BMI group power (19%).
Pearson correlation coefficients showed a significant rela-
tionship between HbA1c and treatment satisfaction. While
associations were low, the relationship of HbA1c level to
treatment satisfaction was significant for the Overall score
(r = -0.16, p < 0.05), Inconvenience of Regimen (r = -0.15,
p < 0.05), Glycemic Control (r = -0.23, p < 0.001), and
Device Satisfaction (r = -0.17, p < 0. 05).
No significant differences were found in the total ITSQ
score or any of the domains during comparisons between
treatment groups, indicating in part the potential that an














Intercept 84.11*** (56.89) 87.24*** (51.36) 78.85*** (41.72) 81.75*** (42.67) 86.43*** (49.64) 84.79*** (54.58)
Retinopathy (N = 0, Y = 1) 7.29 (1.50) 8.94 (1.60) 0.95 (0.15) 2.31 (0.37) 10.17 (1.78) 10.90* (2.13)
Nephropathy (N = 0, Y = 1) 2.08 (0.40) -0.61 (-0.10) 3.68 (0.55) 3.79 (0.56) -2.57 (-0.42) 3.94 (0.71)
Neuropathy (N = 0, Y = 1) -10.56*** (-3.53) -8.81* (-2.54) -12.42** (-3.22) -10.80** (-2.79) -13.43*** (-3.82) -8.00* (-2.54)
Macro Angiopathy (N = 0, Y = 1) -5.18 (-1.09) -1.16 (-0.21) -4.58 (-0.76) -5.63 (-0.92) -5.93 (-1.06) -6.44 (-1.29)
F = 3.622** F = 1.888 F = 2.943* F = 2.280 F = 4.281** F = 2.789*
R2 = 0.069 R2 = 0.037 R2 = 0.057 R2 = 0.044 R2 = 0.080 R2 = 0.054
Adj R2 = 0.050 Adj R2 = -0.018 Adj R2 = 0.038 Adj R2 = 0.025 Adj R2 = 0.062 Adj R2 = -0.035
• * p < 0.05, ** p < 0.01, *** p < 0.001
• IR = Inconvenience of Regime subscale, LF = Lifestyle Flexibility subscale, HC = Hypoglycemic Control subscale, GC = Glycemic Control subscale, 
DD = Device Delivery subscale














Intercept 72.42*** (6.54) 74.63*** (5.89) 68.90*** (4.95) 67.67*** (4.83) 82.53*** (6.32) 73.68*** (6.32)
Age 0.21 (1.51) 0.23 (1.43) 0.35* (2.00) 0.22 (1.24) 0.17 (1.05) 0.14 (0.92)
Gender (0 = M, 1 = F) -2.30 (-0.87) 0.45 (0.15) 0.23 (0.07) -6.42 (-1.92) -4.43 (-1.43) -1.95 (-0.70)
Ethnicity (1 = C, 0 = Other) -0.99 (-0.36) -0.19 (-0.06) -2.80 (-0.81) -1.44 (-0.42) -2.35 (-0.73) 0.90 (0.31)
Length of time with diabetes (↑ longer) -0.17 (-0.66) -0.09 (-0.32) -0.06 (-0.17) -0.42 (-1.30) -0.13 (-0.42) -0.17 (-0.61)
Weight-BMI 0.17 (0.66) 0.01 (0.04) -0.23 (-0.70) 0.50 (1.53) 0.10 (0.31) 0.23 (0.83)
Number of diabetes related co-morbid 
conditions
-3.93* (-2.15) -2.33 (-1.10) -5.68* (-2.46) -5.08* (-2.19) -5.48* (-2.54) -1.93 (-1.00)
F = 1.195 F = 0.538 F = 1.812 F = 1.918 F = 1.497 F = 0.534
R2 = 0.036 R2 = 0.016 R2 = 0.053 R2 = 0.056 R2 = 0.044 R2 = 0.016
Adj R2 = 0.006 Adj R2 = -0.014 Adj R2 = 0.024 Adj R2 = 0.027 Adj R2 = 0.015 Adj R2 = -0.014
• * p < 0.05, ** p < 0.01, *** p < 0.001
• IR = Inconvenience of Regime subscale, LF = Lifestyle Flexibility subscale, HC = Hypoglycemic Control subscale, GC = Glycemic Control subscale, 
DD = Device Delivery subscalePage 5 of 10
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not negatively affect treatment satisfaction.
Examining the combined impact of significant factors
As shown in Table 4, when all previously identified signif-
icant relationships were examined together, neuropathy
continued to have the broadest impact on treatment satis-
faction (Overall and in all 5 subscales). Improved treat-
ment efficacy (HbA1c) maintained the previously
identified significant impacts on overall treatment satis-
faction and in 3 subscales. The number of hypoglycemic
events remained significant only for the Hypoglycemic
Control subscale, however the timing of the hypoglycemic
event significantly impacted overall satisfaction and 3
subscales rather than the previous 5 (Glycemic Control
and Inconvenience of Regimen were no longer signifi-
cant). The impact of age, weight gain and the number of
co-morbid conditions were no longer significant. The R2
for the model was 0.123, suggesting that these combined
factors account for 12% of possible variance of factors that
may impact treatment satisfaction.
Discussion
Clinical wisdom and common sense would presume, and
research has at times supported the idea, that there is a
negative impact of unfavorable treatment characteristics,
burden of treatment and side effects on patient-reported
treatment satisfaction. However, we did not find a signifi-
cant relationship between the number of minor hypogly-
cemic events, weight gain or treatments with 1 vs. 2 daily
injections with overall treatment satisfaction. The rela-
tionship of weight gain to treatment satisfaction was
restricted only to Lifestyle Flexibility. This significant find-
ing may be due to the nature of the items in the Lifestyle
Flexibility domain, as 2 of the 3 items in that subscale
concern eating times and meals. The timing of the
hypoglycemic event (minor hypoglycemic events that
occurred during the day vs. nocturnal episodes) did have
a significantly negative impact on overall treatment satis-
faction. However, it should be noted that it remains
unclear if daytime hypoglycemic events are also more
"feared" or problematic for patients, as nighttime events
may be more difficult to identify or respond to and if they
are major events they may have a greater potential for seri-
ous health consequences. It may also be noteworthy that
minor diurnal events may be more bothersome to daily
functioning, and therefore more negatively influence
treatment satisfaction. On the contrary, minor nocturnal
events such as patients' activity levels are likely to be
higher during daytime hours. As there was only 1 severe
hypoglycemic event during the study, we were not able to
examine the relationship between major events and treat-
ment satisfaction.
Also, contrary to common wisdom, no significant differ-
ences in treatment satisfaction were found between treat-
ment groups despite the fact that BIAsp 70/30 was
administered twice a day (with a pen device) and Glar was
administered once a day (with a syringe) as a fixed charac-
teristic of the treatment arm. This finding suggests that
number of daily injections may not impact overall treat-
ment satisfaction. However, due to the design of this
study, it is difficult to separate out the effect of the number
of daily injections versus the delivery device itself. It may
be that the increased number of daily injections required
for BIAsp 70/30 is balanced by a reported preference for
the pen device over syringe [28-30]. It may also be that
having 1 vs. 2 injections per day is not as important a fac-
tor of treatment satisfaction as the distress experienced by
patients going from being insulin naïve (0 injections per
day) to having begun injections on a daily basis [31].
Given that there is evidence suggesting that BIAsp 70/30 is
also efficacious with once-daily injections [32], additional
research should continue to examine the impact of once-
daily injections with a pen versus syringe on overall satis-
faction, as well as specifically for device satisfaction.












 (n = 197)
Coefficient (t-ratio)
Intercept 92.74*** (12.96) 96.72*** (12.54) 85.36*** (8.46) 86.42*** (8.50) 95.64*** (10.88) 96.55*** (12.63)
Time of event (1 = Active, 7 AM-
11 PM; 0 = Sleeping, 11 PM-7 
AM)
-5.47*** (-4.52) -5.13*** (-4.52) -10.63*** (-6.22) -4.39** (-2.55) -2.98** (-2.00) -5.26*** (-4.06)
Type of event (1 = Symptomatic, 
0 = Not symptomatic)
-11.18 (-1.56) -7.73 (-1.00) -6.54 (-0.65) -15.02 (-1.47) -12.39 (-1.41) -12.25 (-1.60)
F = 11.854*** F = 8.454*** F = 19.837*** F = 4.555*** F = 3.164*** F = 9.929***
R2 = 0.026 R2 = 0.018 R2 = 0.042 R2 = 0.010 R2 = 0.007 R2 = 0.022
Adj R2 = 0.023 Adj R2 = 0.016 Adj R2 = 0.040 Adj R2 = 0.008 Adj R2 = 0.005 Adj R2 = 0.019
• ** p < 0.01, *** p < 0.001
• IR = Inconvenience of Regime subscale, LF = Lifestyle Flexibility subscale, HC = Hypoglycemic Control subscale, GC = Glycemic Control subscale, 
DD = Device Delivery subscalePage 6 of 10
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driver of treatment satisfaction, BIAsp 70/30 was found to
have superior efficacy (improvement in HbA1c) to Glar in
the INITIATE trial, evidence that is supported in a subse-
quent clinical trial [33]. Although there is no data availa-
ble to confirm that patients knew their HbAlc levels, doses
were regularly titrated based on blood glucose levels and
patients self-monitored their blood glucose levels twice
daily. Further, HbAlc level was found to be significantly
related to Overall Satisfaction suggesting that subjects
were aware of treatment efficacy either by information
from the physician or by how they felt. Thus, it is highly
likely that the patients were aware of their HbA1c values,
and able to use this factor when appraising their treatment
satisfaction. Despite superior efficacy, treatment satisfac-
tion was equivalent between the 2 treatment groups. This
finding may be explained by the Decisional Balance
Model of Treatment Satisfaction, whereby Overall treat-
ment satisfaction is determined by the balance between
the positive value of treatment and the negative harms
and inconveniences of the medication [3]. Thus, the
appraisal of treatment satisfaction for a treatment such as
BIAsp 70/30, with superior efficacy when compared to
Glar, but increased minor hypoglycemia and weight gain,
may be equivalent. The Balance Theory model and our
findings in the present analysis are supported by those in
recent trials where competing insulin preparations which
demonstrate disparate side effect and efficacy profiles
have caused non-significant differences in treatment satis-
faction [34]. The Balance Theory model may also help
explain the lack of significant differences in overall treat-
ment satisfaction in pen vs. syringe device studies, even
when there is clearly stated preference for the pen device,
if treatments have equivalent efficacy and safety [28].
It should be noted that the ITSQ overall score is not a truly
independent rating of overall treatment satisfaction as it is
the sum of the subscale items rather than a separate item
assessing overall satisfaction. Post-hoc analyses with this
study data have shown that the correlations between sub-
scales and the overall score are all above 0.77 and a regres-
sion analysis of subscales on the Overall score, found all
subscales were significantly associated with the Overall
score at the 0.01 level, indicating a balance of the subscale
weights contributing to the Overall score. We believe that
in order to fully understand the impact of variables on
treatment satisfaction, the impact on both subscales and
Overall treatment satisfaction should be identified.
Understanding the relative weight of subscales in the over-
all assessment may be valuable as this can help identify
subscales of greater importance given a particular treat-
ment or patient characteristic. Future studies may find it
helpful to include a truly independent measure of overall
satisfaction to further understand the contribution of sub-
scales to overall satisfaction.
In this study we have examined both "simple" regression
models looking at similar types of factors (e.g. demo-
graphic and patient characteristics) as well as more "com-
plex" multivariate models allowing us to test if
significance of variables from the like factor model is
maintained when "competing" against a wide spectrum of














Intercept 108.93*** (13.06) 110.62*** (11.53) 62.46*** (7.52) 84.27*** (43.10) 124.26*** (12.73) 108.68*** (12.34)
Age 0.32* (2.04)
Neuropathy (N = 0, Y = 1) -11.91** (-2.79) -7.97* (-2.38) -11.65* (-2.14) -12.36* (-2.26) -13.42** (-2.69) -8.63** (-2.79)
Retinopathy (N = 0, Y = 1) 9.36 (1.86)
Change in weight (BMI) 7.40 (1.69)
Co-morbid conditions 
(number of diabetic related)
1.43 (0.55) -0.22 (-0.01) 1.83 (0.56) 0.04 (0.01)
HbA1c Level (week 28) -3.29** (-2.88) -3.19* (-2.43) -5.17*** (-3.87) -3.19** (-2.65)
Number of hypoglycemic 
events during day (active 7 
am-11 pm)
-0.53** (-2.72) -0.29 (-1.28) -0.70** (-2.86) -0.81** (-3.26) -0.34 (-1.47) -0.42* (-2.06)
Number of hypoglycemic 
events during night (sleep 11 
pm-7 am)
0.29 (0.72) 0.53 (1.14) 0.71 (1.41) -0.27 (-0.53) 0.15 (0.32) 0.36 (0.84)
F = 65.351*** F = 3.177* F = 4.571*** F = 5.657*** F = 6.093*** F = 4.027**
R2 = 0.123 R2 = 0.062 R2 = 0.125 R2 = 0.103 R2 = 0.138 R2 = 0.095
Adj R2 = 0.100 Adj R2 = 0.043 Adj R2 = 0.098 Adj R2 = 0.085 Adj R2 = 0.115 Adj R2 = 0.072
• * p < 0.05, ** p < 0.01, *** p < 0.001
• IR = Inconvenience of Regime subscale, LF = Lifestyle Flexibility subscale, HC = Hypoglycemic Control subscale, GC = Glycemic Control subscale, 
DD = Device Delivery subscalePage 7 of 10
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of factors, provides a more compressive picture of these
factors and allows use to refine our understanding of their
influence treatment satisfaction. It should be noted that
although statistically significant relationships were identi-
fied in the study, the amount of variance accounted for in
some of the models was small to moderate. Further, as
with all statistical significance, it is unclear what the rela-
tionship is between the statistical and clinical significance
of the findings and it is often difficult to separate out the
unique contributions of variables which may be related,
such as age and co-morbidity. Older type 2 diabetes
patients are more likely to have diabetes related co-mor-
bid conditions and these conditions may negatively
impact a patient's ability to self-manage their disease, cre-
ating a barrier to positive outcomes.
Thus, it is important to understand the unique contribu-
tions of each of these factors to overall as well as domains
of satisfaction. For example, although age did not have a
significant impact on Overall satisfaction, neuropathy, a
painful diabetes related condition, was the strongest pre-
dictor for decreased treatment satisfaction overall and
across subscales. Although it may be difficult for physi-
cians to reduce neuropathy-related pain in diabetes, less-
ening of pain has been found to play only a partial role in
explaining treatment satisfaction for people with chronic
pain. Several studies have found that provider-patient
interaction factors such as confidence, trust and positive
communications are also important for improving satis-
faction [35-37]. Thus, improving provider-patient rela-
tionships for persons with diabetes and neuropathy may
help improve their treatment satisfaction in general and
lead to improved outcomes. This study did not examine
the impact of non-diabetes related co-morbid conditions
on treatment satisfaction and we suggest that this relation-
ship be examined in future studies.
Diabetes related etinopathy was also a significant indica-
tor for the Device Delivery subscale, indicating that visual
impairments and the sensory experience should be taken
into consideration in choosing an insulin delivery device
for a given patient. When pen devices have been com-
pared head-to-head (FlexPen vs. Humalog Pen vs.
syringe), significant improvements in patient preferences
have been found in favor of the devices which improve
the readability of the dose scale and user confidence
[28,38]. The auditory feature of pen devices has also been
shown to affect the patient's confidence in selecting the
correct dose [39], suggesting that auditory impairments
also be considered when exploring treatment options.
These findings may also help clinicians identify patients
who are most at risk for poor treatment satisfaction, so
that the clinicians can develop targeted treatment plans
for these patients. Certainly, patients with neuropathy or
frequent daytime hypoglycemic events should be targeted
for a discussion regarding their potential dissatisfaction
with treatment. Additionally, their compliance and diabe-
tes self-management behavior, critical factors for diabetes
treatment success, should be assessed to identify if these
behaviors have been negatively affected by their dissatis-
faction. Finally, although cost of treatment was not exam-
ined in this study, it should be noted that biphasic insulin
has been projected to be cost-effective therapy vs. basal
insulin alone for long-term treatment [40,41]. Given the
superior efficacy and equivalent patient-reported treat-
ment satisfaction between these treatments, it may be rea-
sonable for clinicians to consider the estimated
improvements in quality-adjusted life expectancy along
with potential cost savings associated with complication
reductions.
Understanding the complex and multidimensional nature
of treatment satisfaction as well as the interaction between
factors that may impact how persons with diabetes
appraise their treatments is still evolving. This study has
begun to examine factors that may impact these relation-
ships; considerably more research will be required to fur-
ther unravel the myths and the realties of treatment
satisfaction in diabetes. There are some shortcomings of
this study that should be noted so that future research can
address these issues. First, although satisfaction with pre-
vious treatments may significantly impact satisfaction
with new treatments [42], the reality is that it is often dif-
ficult or unfeasible to assess. The lack of baseline treat-
ment satisfaction also prevents the assessment of
responsiveness of a measure to differences in treatment.
These methodological challenges present limitations both
in the broader treatment satisfaction literature and in this
study. As the subjects were insulin naïve at baseline, pre-
vious insulin treatment satisfaction could not be meas-
ured. However, the absence of any differences in baseline
demographic or health characteristics in the sample in
combination with the study entry criteria requiring all
subjects to have failed OADs, suggests that baseline differ-
ences in treatment satisfaction would not have been sig-
nificant. Furthermore, a 4 week run-in period prior to the
addition of the study insulin ensured that all randomized
subjects were stabilized on an identical OAD regimen at
baseline. It is also known that RCT populations are gener-
ally not representative of the entire population. Therefore,
it would be very informative to examine these relation-
ships in a more representative diabetic population such as
in a clinic-based study. Additionally, although this study
examined potential baseline patient/disease characteris-
tics and key treatment outcomes that may influence treat-
ment satisfaction, data on other important ongoing
treatment factors such as burden and compliance were not
collected. There may also be other diabetes as well as nonPage 8 of 10
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sample, which may impact treatment satisfaction. These
additional influences should be considered when looking
at the broader spectrum of variables that may or may not
impact treatment satisfaction. Inclusion of these variables
or other potential drivers of treatment satisfaction may
have increased the amount of variance in predicting treat-
ment satisfaction in this study.
Conclusion
Using baseline and end of study treatment effect data
from a randomized controlled trial comparing the efficacy
of BIAsp 70/30 (administered BID via pen device) and
Glar (administered QD via syringe), and by correlating it
to measured responses in the ITSQ, we examined the rela-
tionship between treatment satisfaction, patient/disease
characteristics, treatment outcomes, and treatment
groups. By assessing these factors independently, certain
significant relationships were identified. However, not all
of these significant findings survived when examined in
combination with each other. Thus, in order to more
accurately characterize the impact of patient/disease char-
acteristics and treatment outcomes on treatment satisfac-
tion, a more comprehensive approach at capturing data
on all potentially relevant variables is necessary. This
approach can enhance our understanding of factors that
exert enduring or broader impacts on treatment satisfac-
tion.
The perfect drug for diabetes would improve efficacy with
no side effects, and the perfect patient with diabetes
would be otherwise healthy. However, given the real
world, clinicians will need to balance the advantages and
disadvantages of various treatments and patient types,
and aim to more fully understand the myths and realities
of patient-reported treatment satisfaction to identify the
optimal treatment for a given patient.
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